News & Events

Upcoming Conferences

Thursday, December 31, 2020

Please note: Sekisui XenoTech attends too many events to be able to list them all here. If you would like to meet with us at a particular event that you do not see listed below, please contact us to schedule a meeting. Thank you!

Read more

2020 Seminar Series: Expanding Knowledge of Your Drug's ADME and DDI

Wednesday, September 23, 2020

We'll be hosting seminars on ADME & DDI Updates throughout 2020, featuring cocktails and guest speakers...

Read more

SEKISUI XenoTech Receives New US Patent for a Method to Evaluate Xenobiotics as Immune-Modulators of Drug Transport and Metabolism in Hepatocytes

Tuesday, May 12, 2020

SEKISUI XenoTech has been awarded US patent # 10,648,968 “In vitro test system to evaluate xenobiotics as immune-modulators of drug transport and metabolism in human hepatocytes.” This expands the patent to include small molecule drugs in addition to large molecule/biologics...

Read more

Webinar: In Vitro Inhibition Studies - Elements of Design and Important Considerations in Data Analysis

Wednesday, May 6, 2020

Frequently asked questions about inhibition studies, recommendations for successful regulatory submission, critical considerations in design and more...

Read more

SEKISUI XenoTech Expands Access to Top-Tier DDI Expertise & Consultancy

Monday, May 4, 2020

SEKISUI XenoTech is expanding opportunities for clients to work with top-tier consultants to evaluate drug-drug interaction potential of their drug candidate and bolster their preclinical data package for regulatory submission...

Read more

Webinar: Comparing the Final FDA, EMA & PMDA In Vitro DDI Guidance Documents

Tuesday, April 21, 2020

In January, the FDA published its final guidance for industry on in vitro drug-drug interaction studies. Dr. Ogilvie offers his expert perspective on major changes, whether they will impact your development plans, how the guidance compares with the EMA and PMDA in vitro guidance documents and how to harmonize your drug development strategies to meet the expectations of all three...

Read more

2020 SOT Online Meeting

Friday, April 3, 2020

Since SOT's 59th Annual Meeting and ToxExpo has been canceled due to COVID-19 concerns, we are moving our presentations online...

Read more

New Head of KC-based Drug Development CRO poised for further growth and expansion

Tuesday, January 28, 2020

SEKISUI XenoTech announces the promotion of Dr. Darren Warren to President and Chief Executive Officer...

Read more

SEKISUI XenoTech Celebrates 25th Anniversary

Tuesday, December 10, 2019

This year at SEKISUI XenoTech we celebrate our 25th birthday, and our Japan branch turns 64! Read about our journey from a small academic research lab to the trusted global Contract Research Organization we are today, as well as our sister lab's path to becoming the top ADME CRO in Japan...

Read more

Webinar: Drug Metabolism Related Safety Considerations in Drug Development

Thursday, December 5, 2019

With the close of our 2019 Drug Metabolism Updates Seminar Series, Dr. Wienkers will be presenting his primary keynote topic as a webinar for all of those who could not attend one of our seminar events. His presentation will touch upon strategies for building phase appropriate packages for metabolites to account for pharmacological activity, potential drug interaction and associated metabolism-dependent drug safety concerns...

Read more

2019 EBF Open Symposium

Wednesday, November 20, 2019

We'll be exhibiting and presenting at the 12th EBF Open Symposium on Nov. 20-22nd in Barcelona, Spain...

Read more

2019 ACT Meeting

Sunday, November 17, 2019

We'll be exhibiting and presenting at the 2019 ACT Meeting on Nov. 17-20th in Phoenix, AZ...

Read more

2019 AAPS PharmSci 360

Sunday, November 3, 2019

We'll be exhibiting and presenting at AAPS PharmSci 360 on Nov. 3-6th in San Antonio, TX...

Read more

GMP Annual Symposium 2019

Wednesday, October 16, 2019

We'll be exhibiting and presenting at the GMP Annual Symposium on Oct. 16-18th in Lyon, France...

Read more

PBSS Vancouver Workshop on Preclinical Development

Wednesday, October 9, 2019

We'll be exhibiting and presenting at the PBSS Vancouver Workshop on Preclinical Development & IND/CTA Filings on Oct. 9th...

Read more


Sunday, September 8, 2019

We'll be exhibiting and presenting at the 55th EUROTOX Congress on Sept. 8-11 in Helsinki...

Read more

SEKISUI XenoTech Announces Expanded Consulting Opportunities Available to Clients

Thursday, September 5, 2019

SEKISUI XenoTech now provides the opportunity for clients to work with top-tier consultants to analyze critical components of absorption, distribution, metabolism, and excretion (ADME) of their drug candidate to optimize the data package for regulatory submission. There are myriad options for preclinical tests in terms of which studies to perform when, and regulatory approval is only granted when the data paints a complete picture...

Read more

SEKISUI XenoTech Announces Enhanced Synergy in ADME Testing Services

Tuesday, July 2, 2019

SEKISUI XenoTech is collaborating with the Drug Development Solutions Center to offer a full suite of nonclinical testing services specializing in the evaluation of Absorption, Distribution, Metabolism, and Excretion (ADME) in potential new drugs...

Read more

SEKISUI XenoTech Achieves Record Revenue and Employment Numbers

Tuesday, May 21, 2019

SEKISUI XenoTech will celebrate its 25th anniversary this November, coming into the year with record-breaking achievements. Expansions reflect growth in the fiscal year, which ended March 31, 2019, resulting in the highest headcount in company history with new hires in many departments across the organization...

Read more

Webinar: Transporters of Emerging Importance in Drug Development - Beyond the Guidance Documents

Thursday, May 16, 2019

In this webinar, Dr. Brian Ogilvie will discuss in vitro transporter additions and eliminations in the updated 2017 FDA guidance, OCT1 evaluation in FDA versus EMA official documents, 2018 ITC paper discussing OCT1 and other important transporters, atypical routes of administration...

Read more

Webinar: In Vitro Induction Studies: Elements of Design and Important Considerations in Data Analysis

Wednesday, April 24, 2019

In this webinar, Dr. Joanna Barbara will discuss standard enzyme induction study considerations, FDA guidance requirements, required endpoints for IND submission, 3A induction and associated challenges, next-step recommendations...

Read more

Boston Society Transporter Workshop

Thursday, April 11, 2019

We'll be exhibiting and presenting at the Boston Society Transporter Workshop on Apr. 11th in Cambridge, MA...

Read more

2019 SOT Meeting & ToxExpo

Sunday, March 10, 2019

We'll be exhibiting and presenting at the SOT 2019 Annual Meeting on Mar. 10-14th in Baltimore, MD...

Read more

Webinar: In Vitro Evaluation of Immunomodulating Drugs as Perpetrators of Drug Interactions

Wednesday, February 20, 2019

On October 15th, 2018, Sekisui XenoTech presented on "In Vitro Direct and Cytokine-Mediated Effects of Therapeutic Peptides and other Biologics on CYP Enzymes" at the Peptide ADME Discussion Group Workshop in Gothenburg, Sweden. Following subsequent requests for a follow-up webinar, Dr. Czerwinski will be presenting on the following subjects...

Read more

Sekisui XenoTech Expands Partnership for Japanese Collection of Research Bioresources Cell Bank (JCRB) Distribution

Tuesday, January 8, 2019

After 3 years as the official distributor of JCRB cell lines in North America, Sekisui XenoTech has expanded its agreement with the National Institute of Biomedical Innovation to include distribution to Europe. Scientists in both regions will now be able to utilize Sekisui XenoTech in order to easily receive just about any type of cell line that they may need for their research...

Read more

Webinar: Understanding P-gp & BCRP Inhibition Assay Design & Outcomes

Tuesday, December 11, 2018

Andrea Wolff, Sekisui XenoTech Director of Services Logistics, recently provided a webinar to the SimCyp transporter discussion group on P-gp and BCRP Inhibition. For those who did not have the opportunity to hear her presentation, we hosted a follow-up webinar on Dec. 11th...

Read more

Sekisui XenoTech Announces Creation of Scientific Advisory Board (SAB)

Wednesday, December 5, 2018

Sekisui XenoTech has created a Scientific Advisory Board (SAB) of renowned ADME / DMPK scientists and thought leaders in the pharmaceutical industry...

Read more

2018 Liver Meeting

Friday, November 9, 2018

Dr. Maciej Czerwinski will be presenting at the AASLD Liver Meeting, Nov. 9-13th in San Francisco, CA...

Read more

ACT 2018

Sunday, November 4, 2018

We'll be exhibiting and presenting at the ACT 2018 Annual Meeting on Nov. 4-7th in Palm Beach, FL...

Read more

DMDG & Swedish Academy of Pharmaceutical Sciences Meeting

Tuesday, October 16, 2018

We'll be exhibiting and presenting at the DMDG SPS Joint Meeting on Oct. 16-18th in Gothenburg, Sweden...

Read more

PBSS San Francisco Workshop on Drug-Drug Interactions

Tuesday, October 16, 2018

Sekisui XenoTech will be at the PBSS San Francisco Workshop on Drug-Drug Interactions on Oct. 16th...

Read more

Peptide ADME Discussion Group Workshop

Monday, October 15, 2018

Dr. Brian Ogilvie will be presenting at the Peptide ADME Discussion Group Workshop on Oct. 15th in Gothenburg, Sweden...

Read more

Webinar: Improving hepatocyte pooling, activity and lab efficiency

Thursday, September 27, 2018

Cryopreserved cell pellets allow for distinct benefits to hepatocyte performance, efficiency in the lab, and test system design...

Read more

Celebrating 10 Years of Sekisui XenoTech

Tuesday, September 18, 2018

10 years ago, Sekisui Chemical Company acquired XenoTech and the future of the groundbreaking, innovative CRO was assured. The combination of the already successful XenoTech and the vast and ever-growing reach and resources of Sekisui combined to make a partner for pharmaceutical companies and other product developers that needed quality test systems and services to facilitate the development of safe medicines and products...

Read more

Sekisui XenoTech Adds Monkey, Rodent Hepatocytes to Patented CryostaX Product Line

Wednesday, September 12, 2018

Sekisui XenoTech is expanding its patented CryostaX® hepatocytes selection to include pooled Sprague-Dawley ratCD-1 mouse and Cynomolgus monkey...

Read more

Sekisui XenoTech Receives New US Patent for Evaluating Xenobiotic Drug Metabolism in Hepatocytes

Tuesday, July 17, 2018

Sekisui XenoTech has been awarded US patent # 10,001,471 for evaluating xenobiotics as immune-modulators of drug transport and metabolism in human hepatocytes...

Read more

Webinar: Challenges & Solutions In Today’s In Vitro Transporter Research Landscape

Wednesday, June 20, 2018

On June 20th, Dr. Joanna Barbara, Sekisui XenoTech VP of Scientific Operations, will discuss ramifications of recent FDA in vitro DDI guidance changes to drug transporter study designs, challenges from diverse compounds in otherwise straightforward assays, solutions to problems associated with specific compound characteristics and case studies of problematic observations or data and the creative methods of troubleshooting that were applied...

Read more

Webinar: Patient-Derived Tumor Organoids for Personalized Medicine & Targeted Drug Discovery

Wednesday, May 30, 2018

Patient-derived tumor organoids (PDOs) are cell aggregates produced by in vitro cell cultures of tumor tissue resected from patients. It is thought that PDOs better represent characteristics of tumor tissues in human body than ordinary cell lines. Therefore, they are considered as a more effective tool for the elucidation of cancer mechanisms and evaluation of anti-cancer agents. During the Fukushima Translational Research project*, PDOs were determined to be more similar to clinical tumor samples than ordinary cell lines in terms of gene expression profiling and thusly were coined as Fukushima PDOs (F-PDOs). This webinar is designed to introduce F-PDOs and present their features as well as the evaluation results of anti-cancer agents using F-PDOs...

Read more

Sekisui XenoTech Adds Fatty Liver Disease Tissue Arrays, Microsome Pool to Research Biobank

Tuesday, April 3, 2018

Sekisui XenoTech now offers human liver tissue microarrays and a microsomal pool for studying and developing new treatments for fatty liver disease (FLD). The microsomes and arrays feature non-alcoholic steatohepatitis (NASH) and other liver tissue from the company’s Research Biobank...

Read more

Sekisui XenoTech Hiring and Growing to Meet Customer Demand

Wednesday, January 3, 2018

The company hired a record number of new staff over the past year in order to meet current demand for its products and services, which are utilized to optimize the discovery, development, and approval of new drugs and other compounds. Several previous Sekisui XenoTech employees also returned to the company...

Read more

Webinar: Comparison Between the New US FDA and Japan PMDA In Vitro DDI Guidance Documents…

Tuesday, December 19, 2017

After recent revisions to the Japan PMDA 2014 guideline and US FDA 2012 draft guidance for industry on in vitro drug-drug interaction (DDI) studies, Drs. Andrew Parkinson, XPD Consulting, and Brian Ogilvie, Sekisui XenoTech, will offer their expert perspectives on major changes and differences between the two agencies’ in vitro guidance documents, and how to harmonize your drug development strategies to meet the expectations of both...

Read more

Sekisui XenoTech Appoints New COO

Wednesday, October 18, 2017

Sekisui XenoTech has announced the appointment of Dr. Darren Warren, PhD, as the company’s new Chief Operating Officer. Dr. Warren has over 15 years of leadership experience with Contract Research Organizations (CROs) and almost 30 years of leadership experience in the pharmaceutical industry...

Read more

New Enhanced AO & XO Activity Test Systems Available, Major CYP Activity Not Significantly Impacted

Monday, August 14, 2017

Sekisui XenoTech has established a method for high aldehyde oxidase and xanthine oxidase activity without significantly impacting major CYP activity in pooled human liver S9 and cytosol in vitro drug development test systems…

Read more

Sekisui XenoTech Awarded Cryopreservation Patent, Achieves Numerous Hepatocyte Enhancements

Tuesday, May 9, 2017

Sekisui XenoTech was issued U.S. Patent No. 9,642,355 for the “CRYOPRESERVATION OF CELLS AND SUBCELLULAR FRACTIONS,” specifically related to the CryostaX® test systems, the only single-freeze pooled hepatocytes in the industry, and enhanced its catalog of hepatocyte products with increased cell yield, viability and more...

Read more

Sekisui XenoTech Adds New Dermal Subcellular Fraction Test Systems

Wednesday, February 1, 2017

Sekisui XenoTech is adding human and minipig to the company’s list of species with dermal subcellular fractions available as standard test systems for the development of safer new products. Subcellular fractions are widely used in drug discovery and preclinical drug development to evaluate the in vitro metabolism of new therapeutics.

Read more

Sekisui XenoTech Introduces Lysosomal Test Systems for Biopharmaceutical Development

Wednesday, October 5, 2016

Hepatic human lysosomes and rat tritosomes are now available as standard test systems. These products contain high concentrations of lysosomal degradative enzymes and constitute advantageous test systems for analysis of catabolism and/or activation for targeted biopharmaceuticals that enter cells through the endosomal-lysosomal pathway...

Read more

Sekisui XenoTech Introduces New Research BioBank

Monday, June 13, 2016

As part of Sekisui XenoTech’s commitment to furthering knowledge of hepatic diseases, the company has begun providing disease-diagnosed tissue samples and hepatocytes through its new Research BioBank.

Read more

XenoTech Provides Genotyped Hepatocytes for Polymorphic Enzyme Drug Metabolism Studies

Tuesday, April 12, 2016

Geneknown™ hepatocytes are genotyped cryopreserved human hepatocytes pooled to study the effects of specific genetic variants on drug metabolism and transport to identify risks of adverse drug interactions present only in genetically-defined subpopulations of patients. Genetically determined transport and metabolism polymorphisms have been recognized by the FDA as having potential safety and efficacy implications. This is particularly important for poor metabolizers in cases of drugs metabolized predominantly by polymorphically expressed enzymes.

Read more

XenoTech Accepting Global Scientific Achievement Award Nominations for 2015

Monday, May 18, 2015

XenoTech is accepting nominations for the 2015 Global Scientific Achievement Award, presented annually in recognition of meritorious, scientific contribution and achievement to further research in the field of ADME / DMPK. The recipient will be recognized at an upcoming industry event and will receive an honorarium, travel support, complimentary meeting registration and a $1,000 donation in their name.

Read more

XenoTech Provides Pooled Human Liver Homogenate for Evaluation of Drug Metabolizing Enzymes and Proteins

Tuesday, April 28, 2015

Sekisui XenoTech now offers pooled human liver homogenate. This test system is ideal for metabolism identification when responsible enzymes are not known, proteomic assays, enzymatic activity studies, etc.

Read more

XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014

Tuesday, April 21, 2015

Contract Research Organization, XenoTech, plans move into new global headquarters and expansion of service offerings after experiencing sizable revenue growth in 2014.

Read more

Case Study: XenoTech Ensures Quality

Monday, April 20, 2015

One company's path to accurate, reliable data in drug discovery: When your lab is one of the last stops before a compound goes into human trials, data quality is vital. Despite increasing throughput and more demanding timelines, one CRO delivers quality - consistently.

Read more

XenoTech Scientists Solve Long-Standing Mystery in Drug Metabolism

Wednesday, January 21, 2015

XenoTech has published a new scientific paper in Drug Metabolism & Disposition that solves the long-standing mystery regarding the lack of in vitro formation in classical test systems and the enzymes responsible for the formation of 3-hydroxydesloratadine, a major active human metabolite of loratadine (Claritin).

Read more

XenoTech Teams Up with JCRB to Provide Access to Over 1,100 Cell Lines in North America

Wednesday, January 7, 2015

XenoTech and the National Institute of Biomedical Innovation have teamed up to bring over 1,100 unique cell lines to the North American market.

Read more

XenoTech Receives US Patent for Its Novel Approach to Evaluate Therapeutic Proteins as Immune Modulators of Drug Metabolism

Tuesday, December 9, 2014

XenoTech has been awarded US patent # 8,846,576 “In Vitro Test System to Evaluate Xenobiotics as Immune-Modulators of Drug Transport and Metabolism in Human Hepatocytes”

Read more

Joint XenoTech / Provectus Article Published by Xenobiotica

Monday, January 27, 2014

XenoTech Aides In Provectus PV-10 Assessment for Drug-Drug Interaction Potential, Published in Xenobiotica

Read more

For Additional Webinars

Tuesday, October 1, 2013

Please visit our Webinar Series page...

Read more

For Additional News

Tuesday, October 1, 2013

Please visit our Blog...

Read more

Contact Us

Contact Us

Questions or inquiries? Use our contact form and we’ll reply as soon as possible.* indicates required field

Request A Quote
Request A Quote

Request A Quote

 Security code